Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Mod-5014, a Long-Acting FVIIa-CTP, Proposing a Novel Prophylactic Treatment Supporting Less Frequent Subcutaneous or Intravenous Injections with a Similar Mechanism of Action to rFVIIa: Proof-of-Concept in Hemophilic Animal Models

Lior Binder, MSc, Ahuva Bar-Ilan, PhD, Malka Hoffman, Gili Hart, PhD

Blood (2015) 126 (23): 4670.

https://doi.org/10.1182/blood.V126.23.4670.4670

Published: 2015

Journal Articles

Mod-5014, a Novel Long-Acting FVIIa Proposing An Improved Prophylactic and On Demand Treatment For Hemophilic Patients Following SC and IV Administration – Comprehensive In -Vitro and In -Vivo evaluation In Preparation For Clinical Studies

Gili Hart, PhD, Oren Hershkovitz, PhD, Ahuva Bar Iilan, Miri Zakar, Lior Binder, Eyal Fima, PhD

Blood (2013) 122 (21): 3578.

https://doi.org/10.1182/blood.V122.21.3578.3578

Published: 2013

Journal Articles

Factor VIIa-CTP, a Novel Long-Acting Coagulation Factor, Displays a Prolonged Hemostatic Effect and Augmented Pharmacokinetics and pharmacodynamics Following IV and SC Administration in Hemophilic Animal Models

Gili Hart, PhD, Oren Hershkovitz, PhD, Ahuva Bar-Ilan, PhD, Uri Seligsohn, MD, Eyal Fima, PhD

Blood (2012) 120 (21): 1114.

https://doi.org/10.1182/blood.V120.21.1114.1114

Published: 2012

Journal Articles

Anti-inflammatory effects of an inflammatory chemokine: CCL2 inhibits lymphocyte homing by modulation of CCL21-triggered integrin-mediated adhesions

Liat Flaishon, Gili Hart, Einat Zelman, Christine Moussion, Valentin Grabovsky, Guy Lapidot Tal, Sara Feigelson, Raanan Margalit, Alon Harmelin, Tamar Avin-Wittenberg, David Shoseyov, Ronen Alon, Jean-Philippe Girard, Idit Shachar

Blood (2008) 112 (13): 5016–5025.

https://doi.org/10.1182/blood-2007-12-129122

Published: 2008

Includes: Supplemental data

Journal Articles

IL-15 regulates immature B-cell homing in an Ly49D-, IL-12–, and IL-18–dependent manner

Gili Hart, Tamar Avin-Wittenberg, Idit Shachar

Blood (2008) 111 (1): 50–59.

https://doi.org/10.1182/blood-2007-07-099598

Published: 2008

Journal Articles

Expression of the chemokine receptor CCR2 on immature B cells negatively regulates their cytoskeletal rearrangement and migration

Liat Flaishon, Shirly Becker-Herman, Gili Hart, Yoram Levo, William A. Kuziel, Idit Shachar

Blood (2004) 104 (4): 933–941.

https://doi.org/10.1182/blood-2003-11-4013

Published: 2004

NARROW

Mod-5014, a Long-Acting FVIIa-CTP, Proposing a Novel Prophylactic Treatment Supporting Less Frequent Subcutaneous or Intravenous Injections with a Similar Mechanism of Action to rFVIIa: Proof-of-Concept in Hemophilic Animal Models

Mod-5014, a Novel Long-Acting FVIIa Proposing An Improved Prophylactic and On Demand Treatment For Hemophilic Patients Following SC and IV Administration – Comprehensive In -Vitro and In -Vivo evaluation In Preparation For Clinical Studies

Factor VIIa-CTP, a Novel Long-Acting Coagulation Factor, Displays a Prolonged Hemostatic Effect and Augmented Pharmacokinetics and pharmacodynamics Following IV and SC Administration in Hemophilic Animal Models

Anti-inflammatory effects of an inflammatory chemokine: CCL2 inhibits lymphocyte homing by modulation of CCL21-triggered integrin-mediated adhesions

IL-15 regulates immature B-cell homing in an Ly49D-, IL-12–, and IL-18–dependent manner

Expression of the chemokine receptor CCR2 on immature B cells negatively regulates their cytoskeletal rearrangement and migration

Email alerts

ASH Publications

American Society of Hematology

Mod-5014, a Long-Acting FVIIa-CTP, Proposing a Novel Prophylactic Treatment Supporting Less Frequent Subcutaneous or Intravenous Injections with a Similar Mechanism of Action to rFVIIa: Proof-of-Concept in Hemophilic Animal Models

Mod-5014, a Novel Long-Acting FVIIa Proposing An Improved Prophylactic and On Demand Treatment For Hemophilic Patients Following SC and IV Administration – Comprehensive In -Vitro and In -Vivo evaluation In Preparation For Clinical Studies

Factor VIIa-CTP, a Novel Long-Acting Coagulation Factor, Displays a Prolonged Hemostatic Effect and Augmented Pharmacokinetics and pharmacodynamics Following IV and SC Administration in Hemophilic Animal Models

Anti-inflammatory effects of an inflammatory chemokine: CCL2 inhibits lymphocyte homing by modulation of CCL21-triggered integrin-mediated adhesions

IL-15 regulates immature B-cell homing in an Ly49D-, IL-12–, and IL-18–dependent manner

Expression of the chemokine receptor CCR2 on immature B cells negatively regulates their cytoskeletal rearrangement and migration

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only